CN121108223A - N-乙酰半乳糖胺（GalNAc）来源的化合物和寡核苷酸 - Google Patents

N-乙酰半乳糖胺（GalNAc）来源的化合物和寡核苷酸

Info

Publication number
CN121108223A
CN121108223A CN202511141891.7A CN202511141891A CN121108223A CN 121108223 A CN121108223 A CN 121108223A CN 202511141891 A CN202511141891 A CN 202511141891A CN 121108223 A CN121108223 A CN 121108223A
Authority
CN
China
Prior art keywords
alkyl
optionally substituted
galnac
independently
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202511141891.7A
Other languages
English (en)
Chinese (zh)
Inventor
李振
朱瑞
迈赫迪·米歇尔·德雅梅尔·努玛
程博
查斯·罗伯特·奥尔松
钱德拉蒙利·奇鲁塔
因德拉森达·雷迪·库梅沙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adalx Pharmaceutical Co ltd
Original Assignee
Adalx Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adalx Pharmaceutical Co ltd filed Critical Adalx Pharmaceutical Co ltd
Priority claimed from CN202180082384.4A external-priority patent/CN116546989A/zh
Publication of CN121108223A publication Critical patent/CN121108223A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202511141891.7A 2020-10-09 2021-10-08 N-乙酰半乳糖胺（GalNAc）来源的化合物和寡核苷酸 Pending CN121108223A (zh)

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US202063089936P 2020-10-09 2020-10-09
US63/089,936 2020-10-09
US202063113801P 2020-11-13 2020-11-13
US63/113,801 2020-11-13
US202063131317P 2020-12-29 2020-12-29
US63/131,317 2020-12-29
US202163141300P 2021-01-25 2021-01-25
US63/141,300 2021-01-25
US202163146276P 2021-02-05 2021-02-05
US63/146,276 2021-02-05
US202163251580P 2021-10-01 2021-10-01
US63/251,580 2021-10-01
CN202180082384.4A CN116546989A (zh) 2020-10-09 2021-10-08 N-乙酰半乳糖胺（GalNAc）来源的化合物和寡核苷酸
PCT/US2021/054318 WO2022076922A1 (en) 2020-10-09 2021-10-08 N-ACETYLGALACTOSAMINE(GAlNAc)-DERIVED COMPOUNDS AND OLIGONUCLEOTIDES

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202180082384.4A Division CN116546989A (zh) 2020-10-09 2021-10-08 N-乙酰半乳糖胺（GalNAc）来源的化合物和寡核苷酸

Publications (1)

Publication Number Publication Date
CN121108223A true CN121108223A (zh) 2025-12-12

Family

ID=81126164

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202511141891.7A Pending CN121108223A (zh) 2020-10-09 2021-10-08 N-乙酰半乳糖胺（GalNAc）来源的化合物和寡核苷酸
CN202511141817.5A Pending CN121108222A (zh) 2020-10-09 2021-10-08 N-乙酰半乳糖胺（GalNAc）来源的化合物和寡核苷酸

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202511141817.5A Pending CN121108222A (zh) 2020-10-09 2021-10-08 N-乙酰半乳糖胺（GalNAc）来源的化合物和寡核苷酸

Country Status (10)

Country Link
US (1) US20240083934A1 (https=)
EP (1) EP4225322A4 (https=)
JP (1) JP2023546369A (https=)
KR (1) KR20230113285A (https=)
CN (2) CN121108223A (https=)
AU (1) AU2021359017A1 (https=)
CA (1) CA3198406A1 (https=)
IL (1) IL302000A (https=)
MX (1) MX2023004170A (https=)
WO (1) WO2022076922A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11649260B2 (en) 2021-06-18 2023-05-16 Hongene Biotech Corporation Functionalized N-acetylgalactosamine nucleosides
EP4396193A4 (en) 2021-08-30 2025-07-02 Hongene Biotech Corp FUNCTIONALIZED N-ACETYLGALACTOSAMINE ANALOGUES
JP2024546585A (ja) 2021-12-15 2024-12-26 ホンジーン バイオテック コーポレイション 官能基化ｎ－アセチルガラクトサミンアナログ
JP2025517196A (ja) * 2022-05-13 2025-06-03 エーダーエックス ファーマシューティカルズ， インコーポレイテッド 合成骨格を有するオリゴヌクレオチド及びその合成
WO2024118503A1 (en) 2022-11-28 2024-06-06 Hongene Biotech Corporation Functionalized n-acetylgalactosamine analogs
CN119019354B (zh) * 2023-05-24 2025-07-22 北京炫景瑞医药科技有限公司 化合物及其制备方法和用途
WO2024240101A1 (zh) * 2023-05-24 2024-11-28 北京炫景瑞医药科技有限公司 GalNAc化合物、缀合物、组合物以及它们的用途
CN119019475B (zh) * 2023-05-24 2026-02-06 北京炫景瑞医药科技有限公司 GalNAc化合物、缀合物、组合物以及它们的用途
WO2025140434A1 (zh) * 2023-12-26 2025-07-03 成都倍特药业股份有限公司 一种肝靶向化合物及其在药物缀合物中的用途
CN121263426A (zh) * 2024-05-09 2026-01-02 石药集团中奇制药技术（石家庄）有限公司 GalNAc衍生物及其寡聚核苷酸缀合物
CN118638166B (zh) 2024-08-15 2024-12-17 北京悦康科创医药科技股份有限公司 含有三氮唑结构的GalNAc化合物及其寡核苷酸缀合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6472378B2 (en) * 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
US6852485B1 (en) * 2002-01-22 2005-02-08 California State University Fullerton Foundation Method for identifying a compound for the treatment of microorganism infections by inhibiting energy storage and utilization in pathogens
AU2009298802A1 (en) * 2008-09-23 2010-04-08 Alnylam Pharmaceuticals, Inc. Chemical modifications of monomers and oligonucleotides with cycloaddition
CN111808084A (zh) * 2008-11-10 2020-10-23 阿布特斯生物制药公司 用于递送治疗剂的新型脂质和组合物
GB201408623D0 (en) * 2014-05-15 2014-07-02 Santaris Pharma As Oligomers and oligomer conjugates
KR20180031025A (ko) * 2015-07-31 2018-03-27 아크투루스 쎄라퓨틱스, 인크. 약물 전달을 위한 다중 리간드 제제
CA3020585A1 (en) * 2016-04-11 2017-10-19 Arbutus Biopharma Corporation Targeted nucleic acid conjugate compositions

Also Published As

Publication number Publication date
EP4225322A4 (en) 2024-12-11
IL302000A (en) 2023-06-01
WO2022076922A1 (en) 2022-04-14
CA3198406A1 (en) 2022-04-14
AU2021359017A9 (en) 2024-09-26
CN121108222A (zh) 2025-12-12
MX2023004170A (es) 2023-06-27
KR20230113285A (ko) 2023-07-28
AU2021359017A1 (en) 2023-05-25
JP2023546369A (ja) 2023-11-02
US20240083934A1 (en) 2024-03-14
EP4225322A1 (en) 2023-08-16

Similar Documents

Publication Publication Date Title
CN121108223A (zh) N-乙酰半乳糖胺（GalNAc）来源的化合物和寡核苷酸
JP7696310B2 (ja) オリゴヌクレオチド組成物およびその方法
JP7766589B2 (ja) オリゴヌクレオチド組成物及びその使用方法
TWI844541B (zh) 寡核苷酸組成物及其使用方法
JP2023526975A (ja) オリゴヌクレオチド組成物及びその方法
KR20250004787A (ko) 올리고뉴클레오티드 조성물 및 이와 관련된 방법
EP3923989A1 (en) Multivalent ligand clusters for targeted delivery of therapeutic agents
EP2726467A2 (en) Macrocyclic insulin-degrading enzyme (ide) inhibitors and uses thereof
EP4404942A2 (en) Compositions for editing mecp2 transcripts and methods thereof
JP2017520586A (ja) ハリコンドリン類似体の合成およびその使用
JP7353281B2 (ja) 大環状化合物およびそれらの使用
JP2019505548A (ja) Ｍｙｃモジュレーターとしてのｍａｘバインダーおよびこれらの使用
WO2025072862A9 (en) Oligonucleotide compositions and methods thereof
CN119486739A (zh) α4β1/7整合素配体缀合的化合物及其用途
WO2025196508A1 (en) Targeted delivery of therapeutic agents to hepatocytes
CN116546989A (zh) N-乙酰半乳糖胺（GalNAc）来源的化合物和寡核苷酸
JP2024506387A (ja) 腎線維症を治療するためのオキサジアゾリルジヒドロピラノ［２，３‐ｂ］ピリジン系ＨＩＰＫ２阻害剤
KR20230004765A (ko) 화합물 및 이의 약학적 용도
CN120112641A (zh) 向细胞内递送siRNA的前药
CN119522230A (zh) 具有合成主链的寡核苷酸及其合成
CN121620379A (zh) 订书钉化肽及其方法
CN119421887A (zh) 环膦酸酯修饰的核苷酸
HK1256225B (en) Oligonucleotide compositions and methods thereof
HK40010323A (en) Oligonucleotide compositions and methods thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination